BioNTech's Pipeline Giveth and Taketh Away as the Street Stays Wary

BioNTech's colorectal cancer vaccine halted, but Gotistobart nearly doubled survival in lung cancer; shares at EUR 83.80 as BMO downgrades.

BioNTech shareholders have grown accustomed to whiplash, and September delivered it in full. Within days, the German biotech watched an mRNA cancer vaccine stumble in colorectal cancer while its partnered antibody posted survival data in lung cancer that the company describes as nearly doubling the median overall survival against docetaxel. The stock, meanwhile, ended Tuesday at EUR 83.80, down 2.2% on the session — a move with no single obvious catalyst, which is precisely what makes the current picture so telling.

A setback the market has largely absorbed

Early in September, an independent committee halted a BioNTech study of its mRNA cancer vaccine in colorectal cancer after concluding the treatment offered no prospect of extending patient survival. Reuters reported that US-listed shares fell 7.5% on the news. Yet the damage has proven shallower than that headline suggests: at EUR 83.75, the closing price sits just 0.5% below the 50-day moving average of EUR 84.17. Panic, in other words, is nowhere to be found. That resilience hints that investors no longer treat BioNTech as a single-product wager, even if the colorectal failure stings both scientifically and financially.

Seoul supplies the counterweight

Against that disappointment, BioNTech and partner OncoC4 used the IASLC World Conference on Lung Cancer in Seoul to present updated Phase 3 data from the PRESERVE-003 trial. The antibody Gotistobart, tested as a monotherapy in previously treated squamous non-small cell lung cancer, extended median overall survival versus docetaxel by what the company called "nearly" double. The patients enrolled had progressed despite PD-(L)1 inhibitors and platinum-based chemotherapy — a group with few effective options left. Reuters characterized the survival benefit as clinically meaningful, the kind of result that can move a stock and, at least partly, overshadow memories of the colorectal miss. For a company long valued almost entirely through Comirnaty, this is the raw material of pipeline hope.

The sell side has already trimmed its enthusiasm

Capital markets tell a cooler story. On September 8, BMO Capital Markets downgraded the shares from Outperform to Market Perform and cut its price target to USD 105. The firm cited a sharper-than-expected erosion of the Comirnaty business, no de-risking of the Pumitamig data before at least 2028, and muted expectations for the mRNA program iNeST. That call is now more than a week old and should not be mistaken for the current mood, but it marks the moment a traditionally supportive house lost patience with BioNTech's transition from vaccine maker to oncology company.

Insider activity has added its own wrinkle. One disclosed transaction involved the sale of 20,500 shares on September 10 at USD 96.31 apiece. Such plans are set in advance precisely to defuse suspicions of insider knowledge — yet investors still find it hard to ignore a CEO selling during a stretch of encouraging trial results.

A share price caught between extremes

The stock itself looks directionless. Since a 52-week high of EUR 105.80 in January, it has shed roughly a fifth of its value, while still trading about a fifth above its March low of EUR 68.35. The monthly tally shows a gain of 5.9%, though the past seven days are slightly negative. Such swings fit an annualized 30-day volatility of 72% — a reading that captures how jittery the market has become, noticeably more so than before the guidance cut more than a month ago, after which the shares had briefly recovered.

COVID is an anchor, not an engine

The COVID franchise remains a cash-flow base rather than a growth driver. In August, BioNTech lowered its 2026 revenue guidance to EUR 1.6 billion to EUR 1.9 billion from EUR 2.0 billion to EUR 2.3 billion, blaming weaker vaccine demand. That revision is now over a month old and appears priced in — background noise, for now, drowned out by the oncology narrative.

What investors are really weighing

The question is not whether Gotistobart or Comirnaty dominates the headlines on any given day. It is whether BioNTech can bridge the gap from a singular vaccine triumph to a broad-based oncology pipeline before the market's patience runs out. The lung cancer data from Seoul are one building block for that story. Whether they suffice to offset institutional skepticism will only become clear when further trial results arrive — and, above all, when hard revenue figures from the oncology business start to land. Holding this stock means living with the swings; the colorectal stumble and the Gotistobart advance together suggest the transformation is genuine, even if the road stays bumpy.